Targeting cancer with peptide aptamers

A major endeavour in cancer chemotherapy is to develop agents that specifically target a biomolecule of interest. There are two main classes of targeting agents: small molecules and biologics. Among biologics (e.g.: antibodies), DNA, RNA but also peptide aptamers are relatively recent agents. Peptid...

Descripción completa

Detalles Bibliográficos
Autores principales: Seigneuric, Renaud, Gobbo, Jessica, Colas, Pierre, Garrido, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2011
Materias:
Research Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248178/
https://www.ncbi.nlm.nih.gov/pubmed/21709317
_version_ 1782220209479745536
author Seigneuric, Renaud
Gobbo, Jessica
Colas, Pierre
Garrido, Carmen
author_facet Seigneuric, Renaud
Gobbo, Jessica
Colas, Pierre
Garrido, Carmen
author_sort Seigneuric, Renaud
collection PubMed
description A major endeavour in cancer chemotherapy is to develop agents that specifically target a biomolecule of interest. There are two main classes of targeting agents: small molecules and biologics. Among biologics (e.g.: antibodies), DNA, RNA but also peptide aptamers are relatively recent agents. Peptide aptamers are seldom described but represent attractive agents that can inhibit a growing panel of oncotargets including Heat Shock Proteins. Potential pitfalls and coming challenges towards successful clinical trials are presented such as optimizing the delivery of peptide aptamers thanks to Nanotechnology.
format Online
Article
Text
id pubmed-3248178
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-32481782012-01-18 Targeting cancer with peptide aptamers Seigneuric, Renaud Gobbo, Jessica Colas, Pierre Garrido, Carmen Oncotarget Research Perspectives A major endeavour in cancer chemotherapy is to develop agents that specifically target a biomolecule of interest. There are two main classes of targeting agents: small molecules and biologics. Among biologics (e.g.: antibodies), DNA, RNA but also peptide aptamers are relatively recent agents. Peptide aptamers are seldom described but represent attractive agents that can inhibit a growing panel of oncotargets including Heat Shock Proteins. Potential pitfalls and coming challenges towards successful clinical trials are presented such as optimizing the delivery of peptide aptamers thanks to Nanotechnology. Impact Journals LLC 2011-06-24 /pmc/articles/PMC3248178/ /pubmed/21709317 Text en Copyright: © 2011 Seigneuric et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
spellingShingle Research Perspectives
Seigneuric, Renaud
Gobbo, Jessica
Colas, Pierre
Garrido, Carmen
Targeting cancer with peptide aptamers
title Targeting cancer with peptide aptamers
title_full Targeting cancer with peptide aptamers
title_fullStr Targeting cancer with peptide aptamers
title_full_unstemmed Targeting cancer with peptide aptamers
title_short Targeting cancer with peptide aptamers
title_sort targeting cancer with peptide aptamers
topic Research Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248178/
https://www.ncbi.nlm.nih.gov/pubmed/21709317
work_keys_str_mv AT seigneuricrenaud targetingcancerwithpeptideaptamers
AT gobbojessica targetingcancerwithpeptideaptamers
AT colaspierre targetingcancerwithpeptideaptamers
AT garridocarmen targetingcancerwithpeptideaptamers

Ejemplares similares